 DARTMOUTH, Nova Scotia--BUSINESS WIRE--- IMV Cancer--IMV Inc. the Company or IMV NASDAQ: IMV; TSX: IMV, a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced the appointment of Dr. Michael Kalos, to its board of directors effective today. Dr. Kalos is an internationally recognized expert in T cell therapy and immunotherapy and brings over 25 years of experience from both industry and academia. His previous career highlights include serving as Vice P 